Detalhe da pesquisa
1.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lancet Oncol
; 22(7): 946-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143969